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1. Introduction 
Dopamine is a neurotransmitter in the brain, which controls feelings of wellbeing. This 
sense of wellbeing results from the interaction of dopamine and neurotransmitters such as 
serotonin, the opioids, and other brain chemicals. Low serotonin levels are associated with 
depression. High levels of the opioids (the brain's opium) are also associated with a sense of 
wellbeing. (Blum et al., 2010).  
Dopamine has been called the “anti-stress” and/or “pleasure” molecule. When released into 
the synapse, dopamine stimulates a number of receptors (D1 – D5), which results in 
increased feelings of wellbeing and stress reduction (Kreek and Koob, 2007). The 
mesocorticolimbic dopaminergic pathway plays an important role in mediating 
reinforcement of natural rewards such as food and sex, as well as unnatural rewards such as 
drugs of abuse (Bruijnzeel et al., 2007). Natural rewards include satisfaction of physiological 
drives (e.g. hunger and reproduction) and unnatural rewards are learned and involve 
satisfaction of acquired pleasures such as hedonic sensations derived from alcohol and other 
drugs, as well as from gambling and other risk-taking behaviors. (Olsen, 2011). 
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The DRD2 gene is responsible for the synthesis of dopamine D2 receptors (Grady et al., 
1989). Further depending on the genotype (allelic form A1 versus A2), the DRD2 gene 
dictates the number of these receptors at post-junctional sites (Blum et al., 1990; Noble et al. 
1991). A low number of D2 receptors leads to hypodopaminergic function. When there is a 
paucity of dopamine receptors, the person is more prone to seek any substance or behavior 
that stimulates the dopaminergic system (Conrad et al., 2010). The D2 receptor has been 
associated with pleasure, and the DRD2 gene has been referred to as a reward gene (Heber 
& Carpenter, 2011). 
Although the DRD2 gene, and especially the Taq1 A1 allele, has been most associated with 
neuropsychiatric disorders in general and in alcoholism in particular, it is likely involved in 
other addictions (e.g., carbohydrate). It may also be involved in co-morbid antisocial 
personality disorder symptoms, especially in children and adults with attention deficit 
hyperactivity disorder (ADHD), or Tourettes Syndrome, and high novelty seeking behaviors 
(Noble, 2003).  
Reward Deficiency Syndrome was first defined in 1996 as a putative predictor of impulsive 
and addictive behaviors (Blum et al., 1996). Herein, “Reward Deficiency Syndrome” or 
“RDS” refers to a group of related addictive behaviors. Dopamine is a major component in 
the mechanisms related to RDS and brain function. Specifically, RDS involves dopamine 
resistance, a form of sensory deprivation of the brain's reward or pleasure mechanisms ( 
Bowirrat & Oscar-Berman, 2005). The syndrome can be manifested in relatively mild or 
severe forms that follow as a consequence of an individual's biochemical inability to derive 
reward from ordinary, everyday activities. The DRD2 A1 genetic variant is also associated 
with a spectrum of impulsive, compulsive, and addictive behaviors (Gardner, 2011). RDS or 
anti-reward pathways unite these disorders and explain how certain genetic anomalies give 
rise to complex aberrant behavior.  
In discussing RDS, specific reference is made to an insensitivity and inefficiency in the 
brain’s reward system. There may be a common neurocircuitry, neuroanatomy, and 
neurobiology for multiple addictions and for a number of psychiatric disorders. Due to 
specific genetic antecedents and environmental influences, a deficiency of for example, the 
D2 receptors may predispose individuals to a high risk for multiple addictive, impulsive, 
and compulsive behaviors. It is well known that alcohol and other drugs of abuse, as well as 
most positive reinforcements (e.g., sex, food, gambling, aggressive thrills, etc.), cause 
activation and neuronal release of brain dopamine, which can decrease negative feelings 
and satisfy abnormal cravings for substances such as alcohol, cocaine, heroin, and nicotine, 
which, among others, are linked to low dopamine function (Blum et al., 2008). 
In individuals possessing an abnormality in the DRD2 gene, the brain lacks enough 
dopamine receptor sites to achieve adequate dopamine sensitivity and function from the 
“normal” dopamine produced in the Reward Center of the brain. Carriers of the A1 DRD2 
gene variant may have unhealthy appetites, abuse cocaine, indulge in overeating (which can 
lead to obesity) or, on the other extreme, be anorexic and/or suffer greater consequences of 
chronic stress (Bau et al., 2000). In these individuals, their addictive brains lead to 
generalized craving behavior. In essence, they seek substances including alcohol, opiates, 
cocaine, nicotine, and/or glucose (all substances known to cause preferential release of 
dopamine at the Nucleus accumbens (NAc)) to activate dopaminergic pathways in order to 
offset their low D2 receptors, which are caused by the dopamine D2 receptor gene Taq1 A1 
allele antecedents (Sullivan et al., 2011). However, evidence is emerging that anterior 
cingulate cortex rather than the NAc  may be involved in operant effort-based decision 
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making (Walton et al., 2009). In addition, the DRD2 A1 polymorphism is also associated 
with abnormally aggressive behavior, which also stimulates the brain’s use of dopamine 
(Chen et al., 2005). 
2. Candidate genes and predisposition to reward dependence behaviors  
RDS is linked to flawed dopamine metabolism, and especially to low D2 receptor density. 
Moreover, RDS results from a dysfunction in the mesolimbic system of the brain, which 
directly links abnormal craving behavior with a defect in the Dopamine D2 Receptor Gene 
(DRD2) as well as other dopaminergic genes (D1, D3, D4, and D5, DATA1, MAO, COMT), 
including many genes associated with the brain reward function (Pinto & Ansseau, 2009), as 
listed in Table 1, below. 
 
R E W A R D  -D E P E N D E N C E -  P A T H 
W A Y 
C A N D I D A T E  G E N E S 
Signal Transduction  ADCY7 
Signal Transduction AVPR1A 
Signal Transduction AVPR1B 
Signal Transduction CDK5R1 
Signal Transduction CREB1 
Signal Transduction CSNKLE 
Signal Transduction FEV 
Signal Transduction FDS 
Signal Transduction FOSL1 
Signal Transduction FOSL2 
Signal Transduction GSK3B 
Signal Transduction JUN 
Signal Transduction MAPK1 
Signal Transduction MAPK3 
Signal Transduction MAPK14 
Signal Transduction MPD2 
Signal Transduction MGFB 
Signal Transduction NTRK2 
Signal Transduction NTSR1 
Signal Transduction NTSR2
Signal Transduction PPP1R1B 
Signal Transduction PRKCE 
_________________________________________ ______________________________________ 
Serotonin  HTRIA 
Serotonin HTRIB 
Serotonin HTR2A 
Serotonin HTR2C 
Serotonin HTR3A 
Serotonin HTR3B 
Serotonin MAOA 
Serotonin MAOB 
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R E W A R D  -D E P E N D E N C E -  P A T H 
W A Y 
C A N D I D A T E  G E N E S 
Serotonin SLC64A 
Serotonin TPH1 
Serotonin TPH2 
_________________________________________ ______________________________________ 
Opioid OPRMI 
Opioid OPRKI 
Opioid PDYN 
Opioid PMOC 
Opioid PRD1 
Opioid OPRL1 
Opioid PENK 
Opioid PNOC 
_________________________________________ ______________________________________ 
GABA GABRA2 
GABA GABRA3 
GABA GABRA4 
GABA GABRA6 
GABA GABRB1 
GABA GABRB2 
GABA GABRB3 
GABA GABRD 
GABA GABRE 
GABA GABRG2 
GABA GABRG3 
GABA GABRQ 
GABA SLC6A7 
GABA SL6A11 
GABA SLC32A1 
GABA GAD1 
GABA GAD2 
GABA DB1 
_________________________________________ ______________________________________ 
Dopamine COMT 
Dopamine DDC 
Dopamine DRD1 
Dopamine DRD2 
Dopamine DRD3 
Dopamine DRD4 
Dopamine DRD5 
Dopamine SLC18A2 
Dopamine SLC6A3 
Dopamine TH 
_________________________________________ ______________________________________ 
Cannabinoid CNR1 
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R E W A R D  -D E P E N D E N C E -  P A T H 
W A Y 
C A N D I D A T E  G E N E S 
Cannabinoid FAAH 
_________________________________________ ______________________________________ 
Cholinergic CHRMI 
Cholinergic CHRM2 
Cholinergic CHRM3 
Cholinergic CHRM5 
Cholinergic CHRNA4 
Cholinergic CHRNB2 
_________________________________________ ______________________________________ 
Adrenergic  ADRA1A 
Adrenergic ADRA2B 
Adrenergic ADRB2 
Adrenergic SLC6A2 
Adrenergic DRA2A 
Adrenergic DRA2C 
Adrenergic ARRB2 
Adrenergic DBH 
_________________________________________ ______________________________________ 
Glycine GLRA1 
Glycine GLRA2 
Glycine GLRB 
Glycine GPHN 
_________________________________________ ______________________________________ 
NDMA GR1K1 
NDMA GRINI 
NDMA GRIN2A 
NDMA GRIN2B 
NDMA GRIN2C 
NDMA GRM1 
_________________________________________ ______________________________________ 
Stress  CRH 
Stress CRHEP 
Stress CRHR1 
Stress CRHR2 
Stress GAL 
Stress NPY 
Stress NPY1R 
Stress NPY2R 
Stress NPY5R 
_________________________________________ ______________________________________ 
Drug Metabolizing  ALDH1 
Drug Metabolizing ALDH2 
Drug Metabolizing CAT 
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R E W A R D  -D E P E N D E N C E -  P A T H 
W A Y 
C A N D I D A T E  G E N E S 
Drug Metabolizing CYPZE1 
Drug Metabolizing ADH1A 
Drug Metabolizing ADH1B 
Drug Metabolizing ADH1C 
Drug Metabolizing ADH4 
Drug Metabolizing ADH5 
Drug Metabolizing ADH6 
Drug Metabolizing ADH6 
Drug Metabolizing ADH7 
_________________________________________ ______________________________________ 
Others BDNF 
Others CART 
Others CCK 
Others CCKAR 
Others CLOCK 
Others HCRT 
Others LEP 
Others NR3C1 
Others SLC29A1 
Others TAC 
Table 1. Genes involved in various Reward Dependence Pathways. 
The genesis of all behavior, be it “normal” (socially acceptable) or “abnormal” (socially 
unacceptable), derives from an individual’s genetic makeup at birth. This genetic 
predisposition, due to multiple gene combinations and polymorphisms, is expressed 
differently based on numerous environmental factors including family, friends, educational 
and socioeconomic status, environmental contaminant exposure, and the availability of 
psychoactive drugs, including food. The core of predisposition to these behaviors is a set of 
genes interacting with the environment , which promote a feeling of wellbeing via 
neurotransmitter interaction at the “reward center” of the brain (located in the meso-limbic 
system), leading to normal dopamine release (Kendler et al 2011). 
 Subjects afflicted with RDS carry polymorphic genes in dopaminergic pathways that result 
in hypo-dopominergic function caused by a reduced number of dopamine D2 receptors, 
reduced synthesis of dopamine (by dopamine beta –hydroxylase), reduced net release of 
pre-synaptic dopamine (from, e.g., the dopamine D1 receptor), increased synaptic clearance 
due to a high number of dopamine transporter sites (dopamine transporter), and low D2 
receptor densities (dopamine D2 receptor), making such people more vulnerable to 
addictive behaviors (Comings and Blum, 2000). The RDS concept  involves shared genes  
and their mRNA expressions and behavioral tendencies, including dependence on alcohol, 
psycho-stimulants, marijuana, nicotine (smoking), and opiates, altered opiate receptor 
function, carbohydrate issues (e.g., sugar-binging), obesity, pathological gambling, sex 
addiction, premeditated aggression, stress, pathological aggression, and certain personality 
disorders, including novelty-seeking and sex addiction. The common theme across all of 
these substances and behaviors is that they induce pre-synaptic dopamine release (Dreyer, 
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2010). Spectrum disorders such as ADHD, Tourettes  Syndrome, and Autism are also 
included due to dopamine dysregulation. As well as other rare mutations (Sundaram et al., 
2010) have been associated with Tourettes and Autism. One example includes the 
association with Neuroligin 4 (NLGN4) is a member of a cell adhesion protein family that 
appears to play a role in the maturation and function of neuronal synapses (Lawson-Yuen et 
al., 2008).  
3. Neurogenetics of reward deficiency syndrome (RDS) 
Since the discovery of the double helix, explorations of brain function in terms of both 
physiology and behavioral traits have resulted in a plethora of studies linking these 
activities to neurotransmitter functions having a genetic basis. The mechanisms underlining 
gene expression and the potential impairments due to polygenic inheritance -- and as such, 
predisposition to addiction and self-destructive behaviors -- have been studied. Our studies 
have shown that the prevalence of the DRD2 A1 allele in Cocaine dependent (CD) subjects 
(n = 53) was 50.9%. It was significantly higher than either the 16.0% prevalence (P < 10(-4)) 
in non-substance abusing controls (n = 100) or the 30.9% prevalence (P < 10(-2)) in 
population controls (n = 265) wherein substance abusers were not excluded. Logistic 
regression analysis of CD subjects identified potent routes of cocaine use and the interaction 
of early deviant behaviors and parental alcoholism as significant risk factors associated with 
the DRD2 A1 allele. The cumulative number of these risk factors in CD subjects was 
positively and significantly (P < 10-3) related to DRD2 A1 allelic prevalence. The data 
showing a strong association of the minor alleles (A1 and B1) of the DRD2 with CD indicates 
that a gene, located on the q22-q23 region of chromosome 11, confers susceptibility to this 
drug disorder (Noble et al.,1993) 
Over half a century of dedicated and rigorous scientific research on the mesolimbic system, 
has provided insight into the addictive brain and the neurogenetic mechanisms involved in 
man’s quest for happiness (Blum et al., 2009). In brief, the site of the brain where one 
experiences feelings of wellbeing is the mesolimbic system. This part of the brain has been 
termed the “reward center”. Chemical messages including serotonin, enkephalins, GABA, 
and dopamine (DA) work in concert to provide a net release of DA at the nucleus 
accumbens (NAc), a region in the mesolimbic system. It is well known that genes control the 
synthesis, vesicular storage, metabolism, receptor formation, and neurotransmitter 
catabolism. The polymorphic versions of these genes have certain variations that could lead 
to an impairment of the neurochemical events involved in the neuronal release of DA. The 
cascade of these neuronal events has been termed “Brain Reward Cascade”. See Figure 1. A 
breakdown of this cascade ultimately leads to a dysregulation and dysfunction of DA. Since 
DA has been established as the “pleasure molecule” and the ”anti-stress molecule,” any 
reduction in its function could lead to reward deficiency and resultant aberrant substance 
seeking behavior and a lack of wellness (Blum & Kozlowski, 1989). 
 It is well –known that humans are biologically predisposed to drink, eat, reproduce, and 
desire pleasurable experiences (Tindell  et al. , 2006, Peciña et al., 2006). Impairment in the 
mechanisms involved in these natural processes lead to multiple impulsive, compulsive, 
and addictive behaviors governed by genetic polymorphisms. While there are a plethora of 
genetic variations at the level of mesolimbic activity, polymorphisms of the serotonergic-2A 
receptor (5-HTT2a), serotonergic transporter (5HTTLPR), dopamine D2 receptor (DRD2), 
dopamine D4 receptor (DRD4), dopamine transporter (DAT1), and Catechol-o-methyl–
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transferase (COMT), and monoamine–oxidase (MOA) genes, as well as other genes, 
predispose individuals to excessive cravings and resultant aberrant behaviors. 
As stated earlier, an umbrella term to describe the common genetic antecedents of multiple 
impulsive, compulsive, and addictive behaviors is RDS. Individuals possessing a paucity of 
serotonergic and/or dopaminergic receptors and an increased rate of synaptic DA 
catabolism, due to high catabolic genotype of the COMT gene, or high MOA activity are 
predisposed to self-medicating with any substance or behavior that will activate DA release 
including alcohol, opiates, psychostimulants, nicotine, glucose, gambling, sex, and even 
excessive internet gaming, among others. Use of most drugs of abuse, including alcohol, is 
associated with release of dopamine in the mesocorticolimbic system or “reward pathway” 
of the brain (Di Chiara, 1995). Activation of this dopaminergic system induces feelings of 
reward and pleasure. However, reduced activity of the dopamine system 
(hypodopaminergic functioning) can trigger drug-seeking behavior. Variant alleles can 
induce hypodopaminergic functioning through reduced dopamine receptor density, blunted 
response to dopamine, or enhanced dopamine catabolism in the reward pathway. Cessation 
of chronic drug use induces a hypodopaminergic state that prompts drug-seeking behavior 
in an attempt to address the withdrawal–induced state (Berridge, 2009). 
Acute utilization of these substances can induce a feeling of wellbeing. But, unfortunately 
sustained and prolonged abuse leads to a toxic pseudo feeling of well being resulting in 
tolerance and disease or discomfort. Thus, low DA receptors due to carrying the DRD2 A1 
allelic genotype results in excessive cravings and consequential behavior, whereas normal or 
high DA receptors results in low craving induced behavior. In terms of preventing 
substance abuse, or excessive glucose craving, one goal is to induce a proliferation of DA D2 
receptors in genetically prone individuals. Experiments in vitro have shown that constant 
stimulation of the DA receptor system via a known D2 agonist in low doses results in 
significant proliferation of D2 receptors in spite of genetic antecedents. In essence (Boundry 
et al., 1996) D2 receptor stimulation signals negative feedback mechanisms in the 
mesolimbic system to induce mRNA expression causing proliferation of D2 receptors. This 
molecular finding serves as the basis to naturally induce DA release to also cause the same 
induction of D2-directed mRNA and thus proliferation of D2 receptors in the human. This 
proliferation of D2 receptors in turn, will induce the attenuation of craving behavior. In fact 
this has been proven with work showing DNA–directed over-expression (a form of gene 
therapy) of the DRD2 receptors and significant reduction in both alcohol and cocaine 
craving-induced behavior in animals (Filtz et al.,1994). These observations are the basis for 
the development of a functional hypothesis of drug–seeking and drug use. The hypothesis is 
that the presence of a hypodopaminergic state, regardless of the source, is a primary cause 
of drug–seeking behavior. Thus, genetic polymorphisms that induce hypodopaminergic 
functioning may be the causal mechanism of a genetic predisposition to chronic drug use 
and relapse. Finally, utilizing the long term dopaminergic activation approach will 
ultimately lead to a common safe and effective modality to treat RDS behaviors including 
Substance Use Disorders (SUD), Attention Deficit Hyperactivity Disorder (ADHD), and 
obesity among other reward deficient aberrant behaviors (Rothman & Glowa, 1995; Peng et 
al., 2010). 
Support for the impulsive nature of individuals possessing dopaminergic gene variants is 
derived from a number of important studies illustrating the genetic risk for drug-seeking 
behaviors based on association and linkage studies implicating these alleles as risk 
antecedents having impact in the mesocorticolimbic system (see Figure 1). 
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Fig. 1. Schematic of Brain reward Cascade Normal and abnormal representation. (A) 
represents the normal physiologic state of the neurotransmitter interaction at the 
mesolimbic region of the brain. Briefly, serotonin in the hypothalamus stimulates neuronal 
projections of methionine enkephalin in the hypothalamus that, in turn, inhibits the release 
of GABA in the substania nigra, thereby allowing for the normal amount of Dopamine to be 
released at the Nucleus Accumbens (NAc; reward site of the brain). (B) Represents 
hypodopaminergic function of the mesolimbic region of the brain. The hypodopaminergic 
state is due to gene polymorphisms as well as environmental elements, including both stress 
and neurotoxicity from aberrant abuse of psychoactive drugs (i.e. alcohol, heroin, cocaine etc). 
Genetic variables include serotonergic genes (serotonergic receptors [5HT2a]; serotonin 
transporter 5HTlPR); endorphinergic genes (the mu OPRM1 gene; proenkephalin (PENK); 
PENK polymorphic 3' UTR dinucleotide (CA) repeats}; GABergic genes (GABRB3); and 
dopaminergic genes (including ANKKI Taq A; DRD2 C957T, DRD4 7R, COMT Val/met 
substitution, MAO-A uVNTR, and SLC6A3 9 or 10R). Any of these genetic and or 
environmental impairments could result in reduced release of dopamine and or reduced 
number of dopaminergic receptors. Taken from Blum et al IIOAB 1(2) 2010. 
In doing association studies that require a representative control sample for a single RDS 
psychiatric diagnosis or for potential subsets of RDS, one limitation relates to controls 
poorly screened for multiple RDS behaviors and other related psychiatric disorders 
(Neiswanger et al.,1995). Missing behaviors that are part of the RDS subset may be the 
reason for spurious results when genotyping for single subsets of RDS behaviors. For 
example, in our unpublished study, an individual may not drink alcohol or use drugs but 
may have other RDS behaviors such as overeating or intensive video-gaming. In support of 
this, a very strong association of the dopamine D2 receptor A1 allele (100%) was found in 
one family (Family A) studied over five generations. In addition, every individual in 
another family, Family B, also had at least one dopaminergic high risk allele (100%) (48% 
carried the DRD2 A1 allele). Moreover, in Family B only three adult individuals exhibited 
no addictive behavior. When compared to results in which 55 RDS subjects carried the 
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DRD2 A1 allele at a frequency of 78.2% and the results of a study in which 597 severe 
alcoholics carried the A1 allele at a frequency of 49.3%, there was a significant difference 
between these two groups (X2=16.9, p<0.001). This demonstrated that the A1 allele’s 
prevalence increases with multiple RDS behaviors. The results from these experiments show 
that multifaceted non-specific RDS behaviors should be considered as the true “reward” 
phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism.  
4. The Genetic Addiction Risk Score (GARS) test 
Very few behaviors depend upon a single gene. Complexes of genes (polygenic) drive most 
of heredity-based human actions, and RDS is no exception (Greven et al., 2011). For 
example, DRD2 and DAT1 gene polymorphisms are significantly associated with reward–
dependent traits such as cocaine dependence (Brousse et al., 2010). As a polygenic disorder 
involving multiple genes and many polymorphisms, RDS likely requires a threshold 
number of RDS-associated polymorphisms in order to manifest in a particular subject. 
Unaffected individuals in the population carry some of these alleles. For example, the 
dopamine D2 receptor gene A1 allele is present in about one-third of unscreened Americans 
(Noble, 2003). 
The GARS test has direct implications for both the diagnosis and targeted treatment of RDS 
behaviors by analyzing the association of dopaminergic genetic polymorphisms. Without 
being bound to a particular theory, in keeping with the concept of common neurogenetic 
mechanisms we believe that RDS is a basic phenotype covering many reward behaviors and 
psychiatric disorders, including spectrum disorders (Blum & Gold, 2011). The test provides 
for the first time a polygenic diagnosis of RDS predisposition. Such tests can be used, for 
example, to determine stratified genetic risk of patients with addictive behaviors upon their 
entry into a treatment facility, as information about an individual’s genetic predisposition to 
RDS based on the analysis of a number of RDS-associated alleles will be very useful.  
4.1 RDS-associated SNPs 
RDS-associated SNPs can be identified by any suitable method, including DNA sequencing 
of patients diagnosed with one or more RDS behaviors. After validation, newly identified 
RDS-associated SNPs can be used in the test. As will be appreciated, once identified and 
validated, the presence, if any, of one or more RDS-associated SNPs in the nucleic acids 
derived from a biological sample taken from a patient can be determined using any suitable 
now known or later-developed assay, including those that rely on site-specific 
hybridization, restriction enzyme analysis, or DNA sequencing. Table 2 below, lists a 
number of particularly preferred RDS- associated SNPs, whereby, the detection of which can 
be used for the GARS test. 
 
GENE SNP 
DRD2 
CTGGACGTCCAGCTGGGCGCCTGCCT[C/T]GACCAGCACTTTGAGG
ATGGCTGTG 
 
AGGAACTCCTTGGCCTAGCCCACCCT[G/T]CTGCCTTCTGACGGCCC
TGCAATGT 
 
CTGCTTCCCACCTCCCTGCCCAGGCC[A/G]GCCAGCCTCACCCTTGC
GAACCGTG 
 
GTCACTATTATGGTTTTTATTACTAT[G/T]GCTCTTTTTGAGGAATTG
GGAAATT 
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GENE SNP 
 
CTGACTCTCCCCGACCCGTCCCACCA[C/T]GGTCTCCACAGCACTCC
CGACAGCC 
 
CCACCAGCTGACTCTCCCCGACCCGT[C/G]CCACCACGGTCTCCAC
AGCACTCCC 
 
ACCCATCTCACTGGCCCCTCCCTTTC[A/C]CCCTCTGAAGACTCCTG
CAAACACC 
 
TTTTGCTGAGTGACCTTAGGCAAGTT[G/T]CTTACCTTCTATGAGCCT
GTTTCCT 
 
TGTGATGAATGGGTGCCAAATACACA[A/G]ATACAGAATCTAAGA
AAACACATGG 
 
CTAGAGGAAGTGATGTTCAACAGACA[A/G]ACAACTGAAGGATGT
GTAGGAATTA 
 
TGGAAGTCATGTGCTTTGTATGAAAC[A/G]CCTTGGAATGCTGATA
AGTTTAATT 
 
GTCTAAAGCAAATGGAACCTTTAGGG[A/G]GAGAGATTTGTGTTTG
CTGTGTCCC 
 
GAGGGGACTGGGGTCAGGCCTCATTC[A/G]GGTTCCCTAGAGTGGA
AAGGATTGG 
 
GTATCAGACAGATCTAGGCTCAAATA[A/C]CAGCTTCAGTTCTCAC
CACCTGTGT 
 
CCTGAGTGCACAGGATGCTGGAGCCT[C/T]CCAGTTTCTCTGGCTTT
CATCTCGT 
 
AATCCCCCAACCCCTCCTACCCGTT[-
/C]CAGGCCGGGGATCGCCGAGGAGGTA 
 
GAGGACCCAGCCTGCAATCACAGCTT[A/G]TTACTCTGGGTGTGGG
TGGGAGCGC 
5HT2A  
GCTCAATGGTTGCTCTAGGAAAGCAG[C/T]ATTCTGAAGAGGCTTC
TAAAGACAA 
 
CTGTGAACTCAGGAGCAAGTGCACAC[A/G]TTGCTTATCACTTACC
AGAAGCATT 
 
CTCTGGTTTTAAGCAAGTCATTTAAT[-
/C/T]GGAGTTTTTTTTCTCCCATAAAATG 
 
AAATGGTCCTACCATCTATCCAGATA[C/T]ACAGCTTAAAAACTTA
GGAGTCTCT 
 
TGCTATTTGTAATGCTGCTTATTAGA[G/T]ACATCGCTGATCCTCCTG
TCAACTC 
 
ATGAACCAAATTGCATGAGCTCTATT[A/G]TGTGCCCCTCTTGTAAT
ATAAAAAT 
 
CAGGCAGAATTTCCACAAATGAAATG[C/G]AAATTCAGATATATAT
CTCTTAATC 
 
TCACTCATAACTGAAGATCATTTCAC[C/T]TTTGAATGAGAATTTGT
CTCTGAAG 
 
TGGGCAGAGGAGGGGAAGGGTCACTG[C/T]ACTCAGGGACAAGAG
AAGGGGTGGG 
 
ATCAGTGTGGTCACTTCACTGCTTGC[C/G]AAGGATTCCATCTAATT
CTGAGGAA 
 
AGGCTCTACAGTAATGACTTTAACTC[C/T]GGAGAAGCTAACACTT
CTGATGCAT 
 
TATGTCCTCGGAGTGCTGTGAGTGTC[C/T]GGCACTTCCATCCAAAG
CCAACAGT 
ANKK1 
GGAGGGGGGTCTTGCCCTCAGCCTCA[C/T]GCAGGTTGGGGTCAGC
CTGACGGGA 
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GGAGGGGGGTCTTGCCCTCAGCCTCA[C/T]GCAGGTTGGGGTCAGC
CTGACGGGA 
 
CCTGCAAGCTGTCGCTGCGCCAGCCC[A/G]GGGAGGTGAGTGTGTG
GGCTGGGCA 
 
ACTTTGCAGCCCAGAATGGGGATGAC[C/G]GCACTGCGCGCCTGCT
CCTGGACCA 
OPRK1 
AATTTCCCAAAAACTACAGTTTTTTT[-
/T]TCTTAGCATGCTATTCAGGTAAACA 
 
TTTGCTAGGTAAGGTTCAGCACCCAT[C/T]TGCTGTGGCCTTCCTAT
GAAACGTA 
 
ATGACTAGTCGTGGAGATGTCTTCGT[A/C]CAGTTCTTCGGGAAGA
GAGGAGTTC 
 
GAAAACACAAGTGTGATCAAATGCCA[C/T]GGACCCACAGGAAGC
TGGTGGCTCT 
 
AAGAAATTGTCTGCATATAAACAAAT[A/G]CATCACATTTCCACAA
AAGACTTTG 
 
TGAGAGCTAATGTTTCAAAGAAACTT[G/T]AAATTCCCAAGATTAA
AATTATTGT 
 
CCCAGTAAGTGAATTAAATACTTTCA[C/T]AGACACTCTCCATCTAG
TAGAACAA 
 
TGATAGGCACTGGTTCTACAGTGAGA[C/T]ATATCTCTCCTAAGTCT
GGTGACAA 
 
ACAGTGGCACGATCTCGGCTCACTGC[A/C]ACCTCCACCTCCCGGG
TTTAAGTGA 
 
TTACCTGGCTAACAGTTTTCTATCTC[C/T]CACACGAGCCTGGTGGG
AGGCAGTG 
 
AGCTCTTGTTATCTTACCATTCCCAC[A/G]TTGATTCTCATTTTTATC
CCTCTCC 
 
TCAAGATAGCTAATTGAGAACAAGCA[C/T]GAGACTCCACTCCTGG
TCCCCAAGC 
 
CCATTTTCTTTTCTTCTTTGCTTGTC[G/T]TTTTTTTCTGTTTGTTTTTCT
TTTC 
 
AGAAAATAACTTTTGCTAGATTCACC[A/G]TTGGTTATAGACCTGC
ATGATCTAA
 
GTGATGTTACCAGCCTGAGGGAAGGA[A/G]GGTTCACAGCCTGATA
TGTTGGTGA
 
AGTTAGCTCTGGTCAAGGCTAAAAAT[C/G]AATGAGCAAAATGGC
AGTATTAACA
 
AATTTTATTAGATTAAACAATTTTTA[A/G]CAGACCTCATGCTTGTT
GGAGATAA
 
GGTCCAGGGTACACAACCAAGCAGCC[A/T]TGCTCTAGAGCCCAG
CAAGACAGGG
 
ACTGAAGAATAATCATGCTTAACTCA[A/G]GAGAAATGCTCCACCA
GACGGGCTG 
 
GCACATTTACTGTTTTGTCTAACCTG[C/T]CTAGCCATTTCAGTCAA
GCTGATTG 
 
GCAATCAGAAAGAAATTCAGTTATTA[C/T]AGTATATGCAAGTCAC
ACTGCAAGC
 
AATGAAACACAAATCATAATCTCTGA[A/G]GCAAATAAGAATGGA
AGGACTCCTG
 
TTTAGGGCAAGTCAGAAAGTCCAAAA[A/G]TGCCTCAGATATTCTG
TGTGAGTGA
 
AAAAACTGGGCCTGAGCTCAGATGAA[C/T]TGGAGAACTGAACTTT
GGCTTAGAA 
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GENE SNP 
 
GAGTCATCAGCTCCCAAGGTTTTCTG[C/T]ATGGCTCTGTTTTTATGA
TTTCTGT 
 
GTGTGTACTGCAGTCTGGTCCCATCG[C/T]ATTGCCTTGTGGGATTT
GGGAGTAG 
COMT  
GCTCCTACGGTCCCTCAGGCTTGGAG[A/G]GTCACTTTAAACAATA
AAAAGCAAC 
 
TGTGGTTACTTTCTGGAGAGAGCATG[C/T]GGCATGCAGGAGCTGG
AGGGGGGGT 
 
AAAAGTTACGCTTAATAATGAATGTT[G/T]CAGCACTTTCTTCTCTT
CAGGTATT 
 
CTGTGAGGCACTGAGGATGCCCTCAC[A/G]CGTGCATCTGCATGTG
GCGTGCATG 
 
CTGGTTTGTGTATGTTCTTGGTAAAC[C/T]AGCCCTTGGTCTTACACA
TCATTTC 
 
GCTTCCCTGTTCTCTTCTGCTCTGTC[C/T]TCTGGTGCCCTGAGGCTG
GCCTCCA 
 
GGCATTTCTGAACCTTGCCCCTCTGC[A/G]AACACAAGGGGGCGAT
GGTGGCACT 
 
ATAAGTAACTGTCGAGAAGATTCTCA[C/T]AGGAGACCACGTGGGT
TGCCTGAAG 
SLC6A3 
AATGTCCTCAGCTGGTTCTTCCCCCA[A/G]TGCCCTGATCCTGGGCT
CACATGTG 
 
 
GAGACGAAGACCCCAGGAAGTCATCC[C/T]GCAATGGGAGAGACA
CGAACAAACC 
 
AAAATCAAGTAATGATTGATTTGTAG[A/G]AGTTTGAGTGAGGCAT
CGGATCCCC 
 
ACCGTGCCCAGCCCTGTGTGGGCATC[A/G]GAGGTGGTTCCCTCTG
GTCCTGTCG 
 
GTCCAGGCCCCAGGAGCTGCCGCAGC[A/G]GGCAGTGGAAGGAAG
GCACGTTCAG
 
CAGCTTCCCCTCCCAACACAGAGGCG[A/C]GGCCCAAGTGCAGGA
CTCACAACGG
 
AAGACACAGTGACGGTATACTCATGA[C/T]GGAATATGATTCGGCC
TTAAAACAA
 
AAGGCGAAGCCGGCGATGGTACGTAC[A/G]TTGGTGACGCAGAAC
AGGGACAGGA
 
GCCATCGCCACGCTCCCTCTGTCCTC[A/G]GCCTGGGCCGTGGTCTT
CTTCATCA
 
TGCTTCCTGCTACCAGCAGGCAGACT[C/T]GGATGGAGGTGGAGGG
GACGAGAGT
 
CACGGTAAAAATACAAGGACAGTGTG[A/T]GCAGCAGAATGGCCA
GGCAGACCAC
 
AGGGTTATTAGGATGCTGTGGTCATG[C/T]CGTGTGTGGATGAGTCC
ATGCTGTT
 
GCCAGGCAGGGGCTGGTGGAGGTGCA[C/G]GGCCTGGAGGAACAC
AGAGCCCAGC
 
AGGAGAGGACGTTTGCGCGATTCTCC[C/G]CAGATCCAGTGTTTCC
CGTCAGCCA
 
GGCTCGTGGCCCTGCGGGCGGATCTT[G/T]GGAAGAGCTTGTTCAC
ACTCACCTA
 
TCGAGGCAGGGCCACCGGGGACGTCC[A/G]AGAACATTGGTGATC
CCTTCCCAGG
 
AATGCAGGCGTGGGACAAGGCAGCTC[C/T]GAGTCCTGCTCAATGG
TTTTGTGAC 
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GAGCTCATCCTTGTCAAGGAGCAGAA[C/T]GGAGTGCAGCTCACCA
GCTCCACCC 
 
GTGGGGAGGGGTGCAGGGGAAGGAGG[A/G]GCAAACCAGAGTGT
CTGTCTTGAGG 
 
AAACACGCTGCTGCTGGATCCAAATG[A/C]CAGAAGTCGCCCTGGC
TGGGGCGGT 
 
CTGCGCGCTGGTGCTCTGGGCAGGGC[G/T]GGGAGGCCGGGCGAG
GACTCGCCAG 
 
GGAGCCAGGACGCGAGGGCGACCCCG[A/T]CGGCGGGAGGGCGG
GGCGGGGCGGA 
HTR3B 
CCTTTACAGCCTTTACCTAAGGCAGT[A/G]CTCTTGCTGACATTCAG
GACACTAA 
 
TTTGGCCTTCTCTCTTGGGCCAAGGA[A/G]TTTCTGCTCTATTGCATG
TTCTCAT 
 
GAGAGCTCCTTGGAGATGGAATAGGC[C/T]CCAAGGTTAGCCTGTA
ATTGCCTCC 
 
CCTTAGCACCTGTGTGTCTATCATTC[C/T]GGGCAGGAAAACTTGCA
CAATTAAA 
PPARG 
AAACTCTGGGAGATTCTCCTATTGAC[C/G]CAGAAAGCGATTCCTT
CACTGATAC 
 
AGGATTTTCTTACATTTAAAGCAGAA[C/T]GACACTACTGATACAC
AAAAGTAAA 
 
GAGAAATCTTCGGAGGGCTCACCAGC[A/G]TCACAAGTAGGTAGA
CCAGAAGAGG 
 
GTTTACAGACCTTGTCAGAGTTGGTA[C/G]TAATTCCAGAATATAAT
CATTTCAA 
 
TGGTTGACACAGAGATGCCATTCTGG[C/G]CCACCAACTTTGGGAT
CAGCTCCGT 
 
GATTTATTTAAATCATCTCTAATTCT[C/T]ACAACTCCGAAAAGATA
AGAAAACA 
 
AGGATTTTCTTACATTTAAAGCAGAA[C/T]GACACTACTGATACAC
AAAAGTAAA 
 
GTTGGGGATCCAGTTGGCCTCATTCT[A/G]AGCTGGCTGTGGATTCA
CAGAAGAA
 
AAGATACGGGGGAGGAAATTCACTGG[A/G]TTTTACAATATATTTT
TCAAGGCAA
 
GAGAAATCTTCGGAGGGCTCACCAGC[A/G]TCACAAGTAGGTAGA
CCAGAAGAGG
ChREBP 
GACAAAAAGCAATTGAGGTCCAGGAG[C/G]TGCCGCCCACCCGGC
TCCTCCTCTG
FTO 
GCTGTCAGCACCTGGTACAAATACCA[A/G]GATAGGGTTTTTGGGG
CCACATTTT
 
GCATGCCAGTTGCCCACTGTGGCAAT[A/C]AATATCTGAGCCTGTG
GTTTTTGCC
 
AGGTTCCTTGCGACTGCTGTGAATTT[A/T]GTGATGCACTTGGATAG
TCTCTGTT 
 
GATGACAACATGCAAACTTTATGGCC[A/G]GAAACCAAAGAGTCA
GGCAAAATAT
 
AAAAGAAAGTAAACATATTTAAGGTC[A/G]TAAATAAGGCCATGT
CTAATAGTGA 
 
AGGAATGTTCTGATGGCTTGGCCCAG[G/T]TGGTGACTGTGCAGAT
AGACTGAAG
 
TCAGCACCCAAGGGACCATCAAAGAG[A/G]CTGTTGTGGAGAGGG
AATCCGAAGG 
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TGGAGTGTTTTTCCTTCACCTTTTCC[A/G]GTCTCTGGGTTGCATCGC
CAGACTG 
 
TGTCTAGCCCTGTGGGTTTACATTAG[A/T]TAGGGTAGGTTATTGCT
GCAACGTA 
 
CTATCCAGGATGGCTCTAAAGGGACT[C/T]CGCTATAGGTTGGGGC
TATGATAGA 
 
GCTTATATTCAAAGCTCCAGGTAAAT[A/G]TAAGATGTTGCTATAAT
TACCTAAG 
 
GGTAGGCAGGTGGATCTGAAATCTCA[C/T]ATAGTACCAAGACACG
TGACTAGGA 
 
TTGATTCTTATACTTTTTTGTTTAGT[C/T]GTTGAAATATGTTGTTTTG
GTTGAA 
 
AATTAGGAAGATTTGAGTAGCTAAAA[A/G]TTCCAAGAGTGGAAT
AATAGTTTTA 
 
TTTGGTGCACTCCCAATTTACTCTAA[A/T]CTTCTACGGGCTTCCTTG
GAGAAAC 
 
GACCTGAAAATAGGTGAGCTGTCAAG[G/T]TGTTGGCAGGGAGAG
GCTCCTCTGG 
 
TGGTTCACTGCATATTCCCAGTAATT[C/G]GAACAATGCCTGACATG
AAGTAGAC 
 
TTAGAATGTCTGAATTATTATTCTAG[A/G]TTCCTTGCGACTGCTGTG
AATTTTG 
 
TTGATTTCGGTAGTCATAACACCACC[C/T]TGGAAGGCACCCTAGA
TAGAGGTCA 
 
TTCATTCTACCTGTCTTTAGTATCAT[A/G]GGGGTAGTTACCTCAGC
GGGGGTAG 
 
TTGCTCAAGGTCACACAGTAACCTTA[A/G]GTAGGCAGGATAAGCT
CTGGTTCTG 
 
TATGATGGTTAGGTTAGGTTGCAAGT[C/T]TTGGAATATATGCAGAG
GAATAACT 
 
TTATAAACCTCTAAAATAGTTACTAA[A/G]TAAGTTATTCTTTTAGG
TATTTTTC 
 
TTTTATTTCCGCAATCACTCCCTAAT[C/G]TTTATTTCTTTTTTGCTTC
GCATCA 
 
TAGCATTTTTCTGGAGCGTAATTTCA[C/T]AATGTGAATCAGAAGTC
TTAATAGT 
 
GAGCACAGGTGGAGAGAAAGGGGAGT[A/G]AGAGAAGCAAAGAA
GAAAAGCCTTT
 
TAGGGACACAAAAAGGGACATACTAC[A/G]TGAATTACTAATATCT
AAGAAAATA
 
ATGAATTACTAATATCTAAGAAAATA[C/T]GATACATTTGAGAACT
TAGATGAAG
 
GAAATGTGGTGTAGACGTGACCCAGG[A/G]GGAAATGAGTTTTGTT
GGACAGATT
 
CTACATCTCCTACTTAGCCGAGGTCT[C/T]TTCACTCTCTGGGCAAG
TCTCCTCA
 
ACACGGCTGAAGAGTCAGGAGTGGGA[C/T]GAAAAATACACTTCA
TTTGTAGGTG
 
GCACATTTATGCCTTTTATATGCCAC[A/G]TACACACGAAAACTccat
atattct
 
AGAGTGAATAAAATTATTTCTAAATT[C/T]ATGCTTCATACCGTGTG
TAATTTAG
 
TGTTGCAACAGAGATGATGGCAGTTT[C/T]GGCCACGGTGTAAGAA
GCAGAGGTG 
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GENE SNP 
 
ACATCTGCCTTCCCAGAGAAAGGAAA[A/G]TCAATGTTTAAAGTCT
ATTTAAAAA 
TNF Alpha 
GGGAAGCAAAGGAGAAGCTGAGAAGA[C/T]GAAGGAAAAGTCAG
GGTCTGGAGGG 
 
GGAGGCAATAGGTTTTGAGGGGCATG[A/G]GGACGGGGTTCAGCC
TCCAGGGTCC 
 
TGGCCCAGAAGACCCCCCTCGGAATC[A/G]GAGCAGGGAGGATGG
GGAGTGTGAG 
 
TCTTTCTGCATCCCCGTCTTTCTCCA[C/T]GTTTTTTTCTCTCCATCCC
TCCCTA 
 
GTTGAATGCCTGGAAGGTGAATACAC[A/G]GATGAATGGAGAGAG
AAAACCAGAC 
MANEA 
CATTTTACAATAGATAAATGCTTGTG[C/T]TACCTAAAGCACTTAGC
ACACAGTT 
Leptin OB 
GCTCTGGGAATGTCTATCCTATGCAA[C/T]GGAGATAAGGACTGAG
ATACGCCCT 
 
ATGCAATGGAGATAAGGACTGAGATA[C/T]GCCCTGGTCTCCTGCA
GTACCCTCA 
 
GGAGCCCCGTAGGAATCGCAGCGCCA[A/G]CGGTTGCAAGGTAAG
GCCCCGGCGC 
 
AAGTTCCTGACCTCTGAATGAGAGGG[A/G]CTGTGTAAGGCCAATG
CCTGGGAGG 
 
AATAAAAATAAATGTTCTTCCTTGCA[A/T]TGAAGTTAAATATGTAA
ATTCTCAA 
 
ACTTAGGTATTAGAGGGTGGCCATTA[C/T]TTGAGAGTGACTATGA
CCACAGTTA 
 
TGGGTGAATGTGTTATGCTCTCTCCC[A/G]CCACCATGTCTTTATAC
CCCCTGAT 
 
CTCCCAGTGGGTGGGAGAGAAAGGAC[A/G]TAAGGAAGCAAGTGG
TAAAGGCCCT 
PEMT 
ATCCCTTCACCAGAGTGATTTCCTCG[A/C]GGCAGGTGCCTGGGGT
AGCCACTGG 
 
GGACTGCCTGGTTGTGCTTCGGACCC[A/G]GAGGCAGACAGAGGA
GGCCTTTGAA 
MAO-A 
CCCACTAGGCAAGCCTCCTAAAAGCA[A/G]TATGGTTGTAGATCAC
TGGAAAATA
 
GTAAACATGCAAACTGAAACATTAGC[A/G]CCCATTTATTCAGCAT
CTTAGAAGA
 
GAGTGAAGGCCAGGTACAGAGGAAAT[A/G]AAGCATTCCAAATAA
TGCCAGGTAA
 
CCAAAGTTAACTTGTGAACCCTTCTA[A/G]TAAACTGCTCCAAGAT
ATGACAAAA
 
GTTTGCCATGGATGAACCACCAGGAT[A/G]GTGGGGGAGACAGAA
AAGGTTGATG
 
GGAAAATTCCCCTTCCCCTAAGACAT[C/T]CACCCTTCTGGTTTGGG
TAATTCCT
 
GCAGAGAGAAACCAGTTAATTCAGCG[G/T]CTTCCAATGGGAGCTG
TCATTAAGT
 
GTGCATGATGTATTACAAGGAGGCC[G/T]TCTGGAAGAAGAAGGGT
AGGCTGCT
 
AGAGAAGGAAGTGGTGTCCCCACAAA[G/T]GAATTGCTAAGGAGT
TCCACAGCCT
 
AAGAGAAAACAAAGCTGAAATGCTGC[A/G]AGTCAATAATATCGT
TGCTTTAACA 
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GENE SNP 
 
TTTGACAACTATTTCTAGAATTTGCA[C/T]TGAACTCTGCTTTTCCTT
TTAAATT 
 
GGTCTCGGGAAGGTGACCGAGAAAGA[C/T]ATCTGGGTACAAGAA
CCTGAATCAA 
CRH 
CTGTCCCACAACATGGGGTCTTACAG[C/T]TCTTTGATGTATCCCCC
CACAGGGG 
 
GCCTCTGGGGTCACCAGGTACATCTT[C/T]GATCTTGGCCACACTGG
AGAGTCAA 
 
TTTCTAAACACAGAGGACTGGTGTTG[C/T]GTTATGCAAAGAAAAA
TGCTTCTTA 
 
AAGACACTCAGGTGCAGGGACCCTCT[A/C]CATTTTTGCCCAGCAG
CAGCCATGC 
 
AGGGCCAGGAACCATGAACCAGCGCG[G/T]GTGGGGGCAGCCTCT
TCAGGCCTGG 
 
GGCACACCAGTCCTTTTGAGCCCCAG[C/T]GTCCCCAGGTTAATAA
CCTAGAATT 
 
TGAACACGGAGGCCACACAAGAGTGG[A/G]TTCCAAGTGAAGGAG
TGACCAACTC 
 
TCCTTTCCTGGGATCACAGAGGGAAG[C/T]GCGGGGGAGCCTAGAG
AGCACCACA 
 
TACAGGTGAAGGAAAGTGATTCTTTC[C/T]CCGTTAACTTTGTTTCA
CGCCAGAT 
 
CCCCCAACCAGAGATGATGATGGGGG[A/G]CAGGGGAGGCACCAA
ACCCTGGGCC 
 
AGCAGCATACCCCTAGGGACCTAGGA[A/G]CAGGGAGGGAGAGA
GGCAGCCCTGG 
 
CAGCTGGCACTGACAGCCTGGGGGGG[-
/C/G]CGCTCTCCCCCTGCAGCCGTGCAGG 
 
GAGCACAAGAAGGCCAGCCCACTGGG[C/G]CCTGGGGCTGCCCTC
GGCAACCGTG 
 
CTGCTTCCCACCAATCAGCACAGCTC[A/C]TGCCTGGGGCTGGGAC
ACACTCCCG
ADIPOQ 
ATCAGAATGTGTGGCTTGCAAGAACC[A/G]GCTCAGATCCTGCCCT
TCAAAAACA
 
GTTCTACTGCTATTAGCTCTGCCCGG[G/T]CATGACCAGGAAACCA
CGACTCAAG
STS 
GATGACAAGCCAGGCAGGGAGGAATG[A/G]ACCTGGATTCCTGGT
GAAGGACGTG
VDR 
GTCAGCGATTCTTAATATAAGAAAAA[A/G]TGGTGAAATGTGTTTA
GAGTGTGCT
 
CCTGGGGTGCAGGACGCCGCGCTGAT[C/T]GAGGCCATCCAGGACC
GCCTGTCCA
 
GTTCCTGGGGCCACAGACAGGCCTGC[A/G]CATTCCCAATACTCAG
GCTCTGCTC
 
CATAAGACCTACGACCCCACCTACTC[C/T]GACTTCTGCCAGTTCCG
GCCTCCAG
 
TGGCCTGCTTGCTGTTCTTACAGGGA[C/T]GGAGGCAATGGCGGCC
AGCACTTCC
 
TGTGGGGGTGGGCCAGCCCAGCTTAG[A/G]TTATCTTGGCTCATTGT
CCACTAGT
DBI 
TCTGTCCTCAGGCCAGGGCTTCGCTG[A/C]AGCCCCGGCCACTCCCT
AGTGCCTG 
 
TACGAACTCACTGTAAAACTCACCTT[C/T]GCCATAAGACCTTCTTC
AACTAAGT 
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GENE SNP 
 
ACAGAGTTTACGAACTCACTGTAAAA[C/T]TCACCTTCGCCATAAG
ACCTTCTTC 
 
GGAGAGAAAACAAAGTCAATGGGGCA[C/T]GTGTGGGAAACCAGC
CTGACCTGTG 
 
TTACAGGGACTTCCAAGGAAGATGCC[A/G]TGAAAGCTTACATCAA
CAAAGTAGA 
GABRA6 
TTGGGAAAGGAGAGTCTGAAGGGACA[A/G]TGCATGGTCGGAGAG
CAGTGACAAT 
 
AAATTGGAAATCTGTAACGCAGCTTC[C/T]GTAAGCATGTGTGGGC
AAAAAAGCA 
 
TTCTTTCCATCTGGCACCTATTTATT[C/G]ACTATTTATGCATTCGTT
GAATTAT 
 
CTCTTTCACCATTGACAAATATTTAT[G/T]GACGACTTACTTTCTATG
TAAGGTC 
GABRB3 
CGTTCAGTTTAGTAAGCAAAGGCTTC[C/T]TGGCTTCTCTGGTGATG
GGGTTTGT 
 
AGCTTACCATTTAAGTAGAACTGTTT[A/G]AGATGCTGGACATTCTA
ATACAATC 
 
CCAAATCTGAAATTTACTTGTCACTT[C/T]AGAGTTGTCTTTGAACG
GAAAGATT 
 
TCTGTTGAGTGATAATCTTTCTCGCA[A/G]ATAACTCACAATATTTA
AAAATTGT 
 
AAGAACTCTTCCATGATTGAAATGGT[A/C]GCACATGGAATAACAT
CGATAAGTT 
 
ACAGCAGGTTGGAGCACAGGGCCTAA[A/G]TGGGAGGCCAGGGAG
GTGGGCAGAG 
 
ATTGCTGATTTTCAGGCAAACTATGT[A/T]ACATGGCTTTCAATGGG
TGCTTGGC 
MTHFR 
GAAGCAGTTAGTTCTGACACCAACAA[A/G]TGGTGATAAGAGGTTG
ATAGCCTAG 
 
GTGGGGGGAGGAGCTGACCAGTGAAG[A/C]AAGTGTCTTTGAAGT
CTTTGTTCTT 
 
CTTGAAGGAGAAGGTGTCTGCGGGAG[C/T]CGATTTCATCATCACG
CAGCTTTTC 
 AGATGTTCCACCCCGGGCCTGGACCC[C/T]GAGCGGCATGAGA 
MLXIPL 
GACAAAAAGCAATTGAGGTCCAGGAG[C/G]TGCCGCCCACCCGGC
TCCTCCTCTG 
 
CAGGTAACTGACCCTTCACACATTTA[C/T]GGTGCCCATCTGACATT
CATAGCAT 
VEGF 
GCGCGCGGGCGTGCGAGCAGCGAAAG[C/G]GACAGGGGCAAAGT
GAGTGACCTGC 
 
AGACATGTCCCATTTGTGGGAACTGT[A/G]ACCCTTCCTGTGTGAGC
TGGAGGCA 
 
AGACATGTCCCATTTGTGGGAACTGT[A/G]ACCCTTCCTGTGTGAGC
TGGAGGCA 
 
ACATCCTGAGGTGTGTTCTCTTGGGC[C/T]TGGCAGGCATGGAGAG
CTCTGGTTC 
 
AGCATTCCCGGGCGGGTGACCCAGCA[C/T]GGTCCCTCTTGGAATT
GGATTCGCC 
 
ATCCTCTTCCTGCTCCCCTTCCTGGG[A/G]TGCAGCCTAAAAGGACC
TATGTCCT 
Table 2. RDS-associated SNPs. 
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4.2 Testing parameters and assay requirements: a note on methodology 
A common class of experiments, known as a multiplexed assay or multiplexed biochemical 
experiment, comprises of reacting a sample known or suspected to contain one more target 
analyte species with a set of “probe” molecules. Multiplexing allows two or more, often 
many more (e.g., 10, 50, 100, 1,000 or more), target analyte species to be probed 
simultaneously (i.e., in parallel). Genome Wide scans have now been used to identify gene 
clusters in alcohol and drug addiction (Agrawal et al., 2010). For example, in a gene 
expression assay, each species of target analyte, usually a nucleic acid (i.e., DNA or RNA) of 
known nucleotide sequence but whose presence in a particular sample is suspected but is 
not known with certainty, can be detected using a short probe nucleic acid (e.g., a 
synthetically produced oligonucleotide) having a nucleotide sequence at least a portion of 
which is sufficiently complementary to the target sequence in the particular target analyte to 
allow stable hybridization under the various assay conditions used (including hybridization 
and stringent washing conditions) so that probe/target hybrids can later be detected using a 
desired detection scheme. As those in the art appreciate, such assays can involve those 
wherein target analyte species are labeled (or not) with a detectable label or wherein the 
various target analyte-specific probe species are labeled (directly or indirectly) with any 
suitable label that can be detected by the detector used with the particular assay format (e.g., 
bead-based formats, gene arrays, etc.). Labels include fluorescent molecules.  
For example, in many known DNA/genomic bead-based multiplex assays, each probe 
species includes a DNA molecule of a predetermined nucleotide sequence and length 
attached to an encoded or otherwise identifiable bead or particle. When a labeled “target” 
analyte (in this case, a detectably labeled (e.g., fluorescently labeled) DNA molecule 
containing a target nucleotide sequence) is mixed with the probes, segments of the labeled 
target analyte selectively bind to complementary segments of the DNA sequence of one of 
the bead-bound probe species. The probes are then spatially separated and examined for 
fluorescence. The beads that fluoresce indicate that molecules of the target analyte have 
attached or hybridized to complementary probe molecules on that bead. The DNA sequence 
of the target analyte can then be determined, as the complementary nucleotide sequence of 
the particular probe species hybridized to the labeled target is known, and identification of 
the encoded bead indicates which probe species was bound to that bead. In addition, in such 
assays the level of fluorescence is indicative of how many of the target molecules hybridized 
(or attached) to the probe molecules for a given bead. As is known, similar bead-based 
assays may be performed with any set of known and unknown molecules, analytes, or 
ligands.  
In such bead-based assays, the bead-bound probes are allowed to mix with samples that 
may contain the target analytes without any specific spatial position; as such, such assays 
are commonly called “random bead assays”. In addition, because the bead-bound probes 
are free to move (usually in a liquid medium), the probe molecules and target analytes have 
a better opportunity to interact than in other assay techniques, such as in a conventional 
planar microarray assay format.  
There are many bead/substrate types that can be used for tagging or otherwise uniquely 
identifying individual beads with attached probes. Known methods include using 
polystyrene latex spheres that are colored or fluorescently labeled. Other methods include 
using small plastic particles with a conventional bar code applied, or a small container 
having a solid support material and a radio-frequency (RF) tag. Still other bead-based 
approaches involve vary small encoded beads, particles, or substrates capable of providing a 
large number of unique codes (e.g., greater than 1 million codes) are known.  
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In multiplex assays designed to simultaneously examine 2-25 or so different target analyte 
species, other assay formats can be adapted for use in the GARS test. Indeed, any format 
suited for analysis of multiple genes, either simultaneously in one or more parallel reactions 
or in different reactions carried out in series or at different times, can readily be adapted for 
use.  
5. Brief description of risk alleles in a number of reward genes 
5.1 Dopamine D2 receptor gene (DRD2) 
The dopamine D2 receptor gene (DRD2) first associated with severe alcoholism is the most 
widely studied gene in psychiatric genetics (Blum et a l., 1990). The Taq1 A is a single 
nucleotide polymorphism (SNP rs: 1800497) originally thought to be located in the 3’-
untranslated region of the DRD2 but has since been shown to be located within exon 8 of an 
adjacent gene, the ankyrin repeat and kinase domain containing 1 (ANKK1). Importantly, 
while there may be distinct differences in function, the mis-location of the Taq1 A allele may 
be attributable to the ANKKI and the DRD2 being on the same haplotype or the ANKKI 
being involved in reward processing through a signal transduction pathway (Neville et  
al.,2004). The ANKKI and the DRD2 gene polymorphisms may have distinct, different 
actions with regard to brain function (Huang et al, 2009). Presence of the A1+ genotype 
(A1/A1, A1/A2) compared to the A– genotype (A2/A2) is associated with reduced receptor 
density. (Noble et al, 1991; Montag et al., 2010; Jönsson et al., 1999). This reduction causes 
hypodopaminergic functioning in the dopamine reward pathway. Other DRD2 
polymorphisms such as the C (57T, A SNP (rs: 6277) at exon 7 also associates with a number 
of RDS behaviors including drug use (Duan et al., 2003). Compared to the T– genotype 
(C/C), the T+ genotype (T/T, T/C) is associated with reduced translation of DRD2 mRNA 
and diminished DRD2 mRNA, leading to reduced DRD2 density and a predisposition to 
alcohol dependence (Hirvonen et al.,2004)  The Taq1 A allele is a predictive risk allele in 
families ( Hill et al., 2008). 
More recently, the DRD2 haplotypes I-C-G-A2 and I-C-A-A1 have been found to occur with 
a higher frequency in alcoholics [P=0.026, odds ratio (OR): 1.340; P=0.010, OR: 1.521, 
respectively]. The rare haplotype I-C-A-A2 occurred less often in alcoholics (P=0.010, OR: 
0.507), and was also less often transmitted from parents to their affected children (1 vs. 7). 
Among the subgroups, I-C-G-A2 and I-C-A-A1 had a higher frequency in Cloninger 1 
alcoholics (P=0.083 and 0.001, OR: 1.917, respectively) and in alcoholics with a positive 
family history (P=0.031, OR: 1.478; P=0.073, respectively). Cloninger 2 alcoholics had a 
higher frequency of the rare haplotype D-T-A-A2 (P<0.001, OR: 4.614) always compared 
with controls. In patients with positive family history, haplotype I-C-A-A2 (P=0.004, OR: 
0.209) and in Cloninger 1 alcoholics, haplotype I-T-A-A1 (P=0.045 OR: 0.460) was less often 
present, confirming that haplotypes, which are supposed to induce a low DRD2 expression, 
are associated with alcohol dependence. Furthermore, supposedly high-expressing 
haplotypes weakened or neutralized the action of low-expressing haplotypes (Kraschewski 
et al 2009). 
5.2 D4 dopamine receptor (DRD4) 
There is evidence that the length of the D4 dopamine receptor (DRD4) exon 3 variable 
number of tandem repeats (VNTR) affects DRD4 functioning by modulating the expression 
and efficiency of maturation of the receptor. (Schoots & Van Tol 2003). The 7 repeat (7R) 
VNTR requires significantly higher amounts of dopamine to produce a response of the same 
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magnitude as other size VNTRs (Oak et al., 2000). This reduced sensitivity or “dopamine 
resistance” leads to hypodopaminergic functioning. Thus 7R VNTR has been associated 
with substance–seeking behavior (McGeary et al., 2007). Survival analysis has revealed that 
by 25 years of age 76% of subjects with a DRD4 7-repeat allele have significantly more 
persistent ADHD compared with 66% of subjects without the risk allele. In contrast, there 
were no significant associations between the course of ADHD and the DAT1 10-repeat allele 
(P=0.94) and 5HTTLPR long allele, suggesting that the DRD4 7-repeat allele is associated 
with a more persistent course of ADHD (Biederman et al., 2009). This is consistent with the 
finding of the presence of the 7R DAT genotype in the heroin addict. Moreover, in a study 
evaluating the role of dopamine D4 receptor (DRD4) exon 3 polymorphisms (48 bp VNTR) 
in the pathogenesis of alcoholism, significant differences in the short alleles (2-5 VNTR) 
frequencies were found between controls and patients with a history of delirium tremors 
and/or alcohol seizures (p = 0.043) (Grzywacz et al., 2009). A trend was also observed in the 
higher frequency of short alleles amongst individuals with an early age of onset of 
alcoholism (p = 0.063). These results indicate that inherited short variants of DRD4 alleles 
(3R) may play a role in pathogenesis of alcohol dependence and carriers of the 4R may have 
a protective effect for alcoholism risk behaviors. It is of further note that the DRD4 7-repeat 
allele is significantly over-represented in the opioid-dependent cohort and confers a relative 
risk of 2.46 (Kotler et al., 1997).  
5.3 Dopamine transporter gene (DAT1) 
The dopamine transporter protein regulates dopamine –mediated neurotransmission by 
rapidly accumulating dopamine that has been released into the synapse (Vandenbergh, 
1998). The dopamine transporter gene (SLC6A3 or DAT1) is localized to chromosome 
5p15.3. Moreover, there is a VNTR polymorphism within the 3’ non-coding region of DAT1 
(Michelhaugh et al., 2001). There are two important alleles that may independently increase 
risk for RDS behaviors. The 9 repeat (9R) VNTR has been shown to influence gene 
expression and to augment transcription of the dopamine transporter protein, resulting in 
an enhanced clearance of synaptic dopamine, yielding reduced levels of dopamine to 
activate postsynaptic neurons. Presence of the 9R VNTR has also been linked to Substance 
Use Disorder (SUD) (Guindalini et al., 2006). Moreover, in terms of RDS behaviors, tandem 
repeats of the dopamine transporter gene (DAT) have been associated with high risk for 
ADHD in children and in adults alike (Vandenbergh et al., 2002; Cook et al., 1995). The 10-
repeat allele is significant for hyperactivity-impulsivity (HI) symptoms (Lee et al., 2007).  
5.4 Catechol-O-methyltransferase (COMT)  
The catechol-O-methyltransferase (COMT) is an enzyme involved in the metabolism of 
dopamine, adrenaline and noradrenaline. The Val158Met polymorphism of the COMT gene 
has been previously associated with a variability of the COMT activity, and alcoholism. Serý 
(2006) found a relationship between the Val158Met polymorphism of the COMT gene and 
alcoholism in male subjects. Serý (2006) found the significant difference between male 
alcoholics and male controls in allele and genotype frequencies (p<0,007; and p<0, 04 
respectively. Interestingly in one of the subjects genotyped herein, who battles with heroin 
as an addiction while carrying the DRD2 A1 allele also carried the low enzyme COMT 
activity genotype (A/A). This is agreement with the work of Cao et al. (2003) who did not 
find an association with the high G/G and heroin addiction. No differences in genotype and 
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allele frequencies of 108 val/met polymorphism of COMT gene were observed between 
heroin-dependent subjects and normal controls (genotype-wise: chi-square=1.67, P=0.43; 
allele-wise: chi-square=1.23, P=0.27). No differences in genotype and allele frequencies of 
900 Ins C/Del C polymorphism of COMT gene were observed between heroin-dependent 
subjects and normal controls (genotype-wise: chi-square=3.73, P=0.16; allele-wise: chi-
square=0.76, P=0.38). While there is still some controversy regarding the COMT association 
with heroin addiction it was also interesting that the A allele of the val/met polymorphisms 
(-287 A/G) found by Cao et al. (2003) was found to be much higher in heroin addicts than 
controls. Faster metabolism results in reduced dopamine availability at the synapse, which 
reduces postsynaptic activation, inducing hypodopaminergic functioning. Generally 
Vanderbergh et al. (1997) and Wang et al. (2001) support an association with the Val allele 
and SUD but others do not (Samochowise et al. 2006).  
5.5 Monoamine – Oxidase A  
Monoamine oxidase-A (MAOA) is a mitochondrial enzyme that degrades the 
neurotransmitters serotonin, norepinephrine, and dopamine. This system is involved with 
both psychological and physical functioning. The gene that encodes MAOA is found on the 
X chromosome and contains a polymorphism (MAOA-uVNTR) located 1.2 kb upstream of 
the MAOA coding sequences (Shih, 1991). In this polymorphism, consisting of a 30-base pair 
repeated sequence, six allele variants containing either 2-, 3-, 3.5-, 4-, 5-, or 6-repeat copies 
have been identified (Zhu & Shih,  1997). Functional studies indicate that certain alleles may 
confer lower transcriptional efficiency than others. The 3-repeat variant conveys lower 
efficiency, whereas 3.5- and 4-repeat alleles result in higher efficiency (Brummett et al., 
2007). The 3- and 4-repeat alleles are the most common, and to date there is less consensus 
regarding the transcriptional efficiency of the other less commonly occurring alleles (e.g., 2-, 
5-, and 6-repeat). The primary role of MAOA in regulating monoamine turnover, and hence 
ultimately influencing levels of norepinephrine, dopamine, and serotonin, indicates that its 
gene is a highly plausible candidate for affecting individual differences in the manifestation 
of psychological traits and psychiatric disorders (Shih et al., 1999). For example, recent 
evidence indicates that the MAOA gene may be associated with depression (Brummett et al., 
2008) and stress (Lee et al., 2009). However, evidence regarding whether higher or lower 
MAOA gene transcriptional efficiency is positively associated with psychological pathology 
as been mixed. The low-activity 3-repeat allele of the MAOA-uVNTR polymorphism has 
been positively related to symptoms of antisocial personality (Ponce et al., 2009) and cluster 
B personality disorders. Other studies, however, suggest that alleles associated with higher 
transcriptional efficiency are related to unhealthy psychological characteristics such as trait 
aggressiveness and impulsivity. High MAO activity and low levels of dopamine are 2 
important factors in the development of alcohol dependence. MAO is an important enzyme 
associated with the metabolism of biogenic amines. Therefore, Huang et al. (2007) 
investigated whether the association between the dopamine D2 receptor (DRD2) gene and 
alcoholism is affected by different polymorphisms of the MAO type A (MAOA) gene. The 
genetic variant of the DRD2 gene was only associated with the anxiety, depression 
(ANX/DEP) ALC phenotype, and the genetic variant of the MAOA gene was associated 
with ALC. Subjects carrying the MAOA 3-repeat allele and genotype A1/A1 of the DRD2 
were 3.48 times (95% confidence interval = 1.47-8.25) more likely to be ANX/DEP ALC than 
the subjects carrying the MAOA 3-repeat allele and DRD2 A2/A2 genotype. The MAOA 
gene may modify the association between the DRD2 gene and ANX/DEP ALC phenotype. 
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Overall, Vanyukov et al (2004) suggested that, although not definitive, variants in MAOA 
account for a small portion of the variance of SUD risk, possibly mediated by liability to 
early onset behavioral problems (Vanyukov et al., 2004).  
5.6 Serotonin transporter gene  
The human serotonin (5-hydroxytryptamine) transporter, encoded by the SLC6A4 gene on 
chromosome 17q11.1-q12, is the cellular reuptake site for serotonin and a site of action for 
several drugs with central nervous system effects, including both therapeutic agents (e.g. 
antidepressants) and drugs of abuse (e.g. cocaine). It is known that the serotonin transporter 
plays an important role in the metabolic cycle of a broad range of antidepressants, 
antipsychotics, anxiolytics, antiemetics, and anti-migraine drugs. Salz et al. (2009) found an 
excess of -1438G and 5-HTTLPR L carriers in alcoholic patients in comparison to the heroin 
dependent group [OR (95% CI)=1.98 (1.13-3.45) and 1.92 (1.07-3.44), respectively]. The A-
1438G and 5-HTTLPR polymorphisms also interacted in distinguishing alcohol from heroin 
dependent patients (df) =10.21 (4), p=0.037). The association of -1438A/G with alcohol 
dependence was especially pronounced in the presence of 5-HTTLPR S/S, less evident with 
5-HTTLPR L/S and not present with 5-HTTLPR.  
5.7 Gamma-aminobutyric acid (GABA) receptor genes 
Gamma-aminobutyric acid (GABA) receptor genes have also received some attention as 
candidates for drug use disorders. One reason for this is that the dopamine and GABA 
systems are functionally interrelated (White, 1996). Research suggests that dopamine 
neurons projecting from the anterior ventral tegmental area to the NAc are tonically 
inhibited by GABA through its actions at the GABAA receptor (Ikemoto, Kohl, & McBride, 
1997). Moreover, it has been shown that alcohol (Theile, Morikawa, Gonzales, & Morrisett, 
2008) or opioid (Johnson & North, 1992) enhancement of GABAergic (through GABAA 
receptor) transmission inhibits the release of dopamine in the mesocorticolimbic system. 
Thus, a hyperactive GABA system, by inhibiting dopamine release, could also lead to 
hypodopaminergic functioning. Because of this, GABA genes are of interest in the search for 
causes of drug use disorders. A dinucleotide repeat (DNR) polymorphism of the GABA 
receptor β3 subunit gene (GABRB3) results in either the presence of the 181-bp G1 or 11 
other repeats designated as non-G1 (NG1). Research indicates that the NG1 is more 
prevalent in children of alcoholics (COAs; Namkoong, Cheon, Kim, Jun, & Lee, 2008). 
Presence of the NG1 has been associated with alcohol dependence (Noble et al., 1998; Song 
et al., 2003). In addition, other GABA receptor genes have also been associated with this 
disorder (Edenberg et al., 2004). 
6. Multiplex analysis and GARS  
There is a need to classify patients at genetic risk for drug seeking behavior prior to or upon 
entry to residential and or non-residential chemical dependency programs. Instead of 
continuing to evaluate single gene associations to predict future drug abuse, it seems 
parsimonious to evaluate multiple genes involved in the brain reward cascade and 
hypodopaminergic antecedents. As described in this example, such methods employ RDS-
associated gene panels to stratify or classify patients entering a treatment facility as having 
low,  moderate, or high genetic predictive risk based on a number of now known and/or 
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later discovered RDS risk alleles. Our laboratory developed a Genetic Addiction Risk Score 
(GARS) for this purpose. This example describes genetic studies for seven RDS-associated 
alleles for six candidate genes in a patient population (n=26) of recovering poly-drug 
abusers (Blum et al., 2010).  
To determine RDS risk severity for each of these 26 patients, the percentage of prevalence of 
the risk alleles was calculated and a severity score based on the percentage of these alleles 
present in a given patient was developed. Subjects carry the following risk alleles: 
DRD2=A1; SLC6A3 (DAT) =10R; DRD4=3R or 7R; 5HTTlRP = L or LA; MAO= 3R; and 
COMT=G. As depicted in Tables 5 and 6, below, Low Severity (LS) = 1-36%, Moderate 
Severity (MS) =37-50%, and High Severity (HS) = 51-100%, scores were assigned. Two 
distinct ethnic populations among the 26 patients were studied. Group 1 consisted of 16 
male Caucasian psycho-stimulant addicts and Group 2 consisted of 10 Chinese heroin-
addicted males. Based on this analysis, the 16 Caucasian 100% of subjects had at least one 
risk allele (see tables 5 and 6). Therefore, using this approach it was found that 81% of the 
patients were at moderate to high risk for addictive behavior. Of particular interest was the 
discovery that 56% of the subjects carried the DRD2 A1 allele (9/16).  
Out of the nine Chinese heroin addicts (Group 2), it was found that 11% (1) were HS, 56% 
(5) were MS, and 33% (3) were LS. These scores were then converted to a fraction and 
represented as GARS, whereby the average GARS was found to be: 0.28 Low Severity; 0.43 
moderate severity; and 0.54 high severity, respectively. Therefore, using GARS it was 
discovered that 67% of the Group 2 patients were at moderate to high risk for addictive 
behavior. As with Group 1, 56% of the Group 2 subjects carried the DRD2 A1 allele (5/9). 
Statistical analysis revealed that the two groups did not differ in terms of overall severity 
(67% vs. 81%) in these two distinct populations. Combining these two independent study 
populations reveals that subjects entering a residential treatment facility for poly-drug abuse 
carry at least one risk allele (100%). Moreover, 74% of the combined 25 subjects who were 
genotyped by SNP analysis had a moderate-to-high GARS. 
The 16 patients of Group 1 were interviewed and evaluated for chemical dependence using 
a standard battery of diagnostic tests and questionnaires. The tests included the following: a 
drug history questionnaire; a physical assessment, urine drug tests; a breathalyzer; complete 
CBC blood test; and a symptom severity questionnaire. The patients were determined to be 
substance dependent according to Diagnostic and Statistical Manual (DSM-IV) criteria. All 
patients were residential in-patients enrolled in 30-90 day chemical dependence 
rehabilitation programs at either of two treatment centers in the U.S.  
Table 3 shows the demographics of the 16 patients, including gender, race, age, and length 
of abstinence. The median age was 29.5 ± 8.8 SD years. The population breakdown was as 
follows: 87.5 % Caucasian and 12.5% Hispanic. The average number of months abstinent for 
the entire population was 9.5 ±23.3. There were 3 pure cocaine-only addicts; 4 cocaine crack 
addicts; and 9 cocaine plus other drugs of abuse (alcohol, opiates and marijuana).  
Table 4 includes genotype data from a functional MRI (fMRI) study in China evaluating 
involving 10 heroin-addicted Chinese males with a median age of 33 ± 7.6 SD years. 
Diagnosis of heroin dependence was also determined in this group using DSM-1 V criteria 
and other behavioral instruments. The average number of months abstinent for the entire 
population was 16 ± 7.9. 
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Median ±st.dev. (min, max) N (total = 16) 
Age 29.5 ±8.80 (19, 48) 16 
Clean time (months) 9.5 ±23.33 (2, 101) 16 
Race = Caucasian 14 
Race = Hispanic 2 
Sex = Male 16 
Primary Substance = Cocaine only 3 
Primary Substance = Crack cocaine 4 
Primary Substance = Cocaine + Other* 9 
Table 3. Demographics of all Caucasian subjects combined. 
 
 Median ±st.dev. (min, max) N (total = 10) 
Age 33 ± 7.57 (20, 44) 10 
Clean time (months) 16 ± 7.91 (1, 24) 10 
Race = Chinese   10 
Sex = Male   10 
Primary Substance =  Heroin only  10 
Primary Substance =  Heroin  + other  0 
*One sample was eliminated because genotyping could not be performed. Source Blum et al 2010. 
Table 4. Demographics of all Chinese subjects combined*. 
6.1 Genotyping 
Genotyping (Blum et al., 2010) was performed as follows. Each patient was also genotyped 
for the following gene polymorphisms: MAOA-VNTR, 5HTTLPR, SLC6A3, DRD4, ANKKI, 
DRD2 TaqIA (rs1800497), and the COMT val158met SNP (rs4680). Genotypes were scored 
independently by two investigators.  
The dopamine transporter (DAT1, locus symbol SLC6A3, which maps to 5p15.3, contains a 
40 base-pair Variable Number Tandem Repeat (VNTR) element consisting of 3-11 copies in 
the 3' untranslated region (UTR) of the gene.  
The dopamine D4 receptor (DRD4), which maps to 11p15.5, contains a 48 bp VNTR 
polymorphism in the third exon, which consists of 2-11 repeats.  
Monoamine Oxidase A upstream VNTR (MAOA-uVNTR). The MAOA gene, which maps to 
Xp11.3-11.4, contains a 30 bp VNTR in the 5’ regulatory region of the gene that has been 
shown to affect expression. A genotype by environment interaction has been reported for 
this polymorphism.  
Serotonin Transporter-Linked Polymorphic region (5HTTLPR). The serotonin transporter 
(5HTT, Locus Symbol SLC6A4), which maps to 17q11.1-17q12, contains a 43 bp 
insertion/deletion (ins/del) polymorphism in the 5’ regulatory region of the gene. A SNP 
(rs25531, A/G) in the Long form of 5HTTLPR has functional significance: The more 
common LA allele is associated with the reported higher basal activity, whereas the less 
common LG allele has transcriptional activity no greater than the S. The SNP rs25531 is 
assayed by incubating the full length PCR product with the restriction endonuclease MspI. 
For all of the above VNTR and ins/del polymorphisms, PCR reactions contained 
approximately 20 ng of DNA, 10% DMSO, 1.8 mM MgCl2, 200 µM deoxynucleotides, with 
7’-deaza-2’-deoxyGTP substituted for one half of the dGTP, 400 nM of appropriate forward 
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and reverse amplification primers, and 1 unit of AmpliTaq Gold® polymerase, in a total 
volume of 20 µl. Amplification was performed using touchdown PCR. After amplification, 
an aliquot of PCR product was combined with loading buffer containing size standard 
(Genescan 1200 Liz) and analyzed with an ABI PRISM® 3130 Genetic Analyzer.  
DRD2 TaqIA (rs1800497). The gene encoding the dopamine D2 receptor maps to 11q23, and 
contains a polymorphic TaqI restriction endonuclease site located within exon of the 
adjacent ANKKI gene that was originally thought to be located in the 3' untranslated region 
of the gene. The A1 allele has been reported to reduce the amount of receptor protein. This 
SNP was assayed using a Taqman (5’Nuclease) assay. 
COMT val158met SNP (rs4680). The gene encoding COMT maps to 22q11.21, and codes for 
both the membrane-bound and soluble forms of the enzyme that metabolizes dopamine to 
3-methoxy-4-hydroxyphenylethylamine. An A→G mutation results in a valine to 
methionine substitution at codons 158/108, respectively.  This amino acid substitution has 
been associated with a four-fold reduction in enzymatic activity. The COMT SNP was 
assayed with a Taqman method.  
6.2 Genetic Addiction Risk Score (GARS) 
In terms of genotyping data it has been determined that when multiple RDS-associated 
genes are analyzed, such as the genes for serotonergic- 2A receptor (5-HTT2a), serotonergic 
transportor (5HTTLPR), (dopamine D2 receptor (DRD2), Dopamine D4 receptor (DRD4), 
Dopamine transporter (DAT1), Catechol-o-methyl –transferase (COMT), and monoamine–
oxidase (MOA), 100% of all subjects carried at least one risk allele. To our knowledge this is 
the first reported attempt to stratify or classify addiction risk by incorporating an algorithm 
formulation that combines genotyping results for a number of RDS-associated risk alleles by 
pre-assigning an allele as a risk allele having predictive value for drug use. Previously, Blum 
et al (1996) using Bayesian statistics it was shown that the DRD2 A1 allele had a predictive 
value of 74.4% for all Reward Deficiency Syndrome (RDS). Here, the subjects studied in this 
investigation had multiple drug abuse relapses and presented to in-patient residential 
treatment programs.  
 
Sub MAOAuVNTR 5HTTLPR 5HTTLPR SLC6A3 DRD4 DRD2 COMT
Any risk 
allele 
SEVERITY* 
GARS 
1 3R S/L S/LG 9R/10R 4R/4R A1/A2 G/G POSITIVE 0.46–MS 
2 3R S/L S/LA 10R/10R 4R/7R A2/A2 G/G POSITIVE 0.62 –HS 
3 3R L/L LA /LG 9R/9R 3R/4R A1/A2 A/G POSITIVE 0.57-HS 
4 4R S/L S/LA 10R/10R 3R/7R A2/A2 G/G POSITIVE 0.46-MS 
5 4R L/L LA/LA 10R/10R 4R/7R A2/A2 A/G POSITIVE 0.62 –HS 
6 3R S/S S/S 9R/10R 4R/7R A2/A2 A/G POSITIVE 0.30 –LS 
7 4R S/L S/LG 10R/10R 4R/4R A1/A1 A/A POSITIVE 0.38 –MS 
8 4R S/L S/LA 9R/10R 3R/4R A2/A2 A/A POSITIVE 0.23-LS 
9 3R L/L LA//LA 9R/9R 4R/7R A2/A2 A/G POSITIVE 0.54-HS 
10 4R L/L LA/LA 9R/10R 4R/4R A2/A2 G/G POSITIVE 0.54 –HS 
11 3R S/L S/ LA 9R/10R 4R/4R A1/A2 G/G POSITIVE 0.54-HS 
12 4R L/L LA/LA 9R/10R 4R/4R A1/A2 A/G POSITIVE 0.54-HS 
13 4R S/L S/ LA 10R/10R 4R/4R A1/A2 A/G POSITIVE 0.46 –MS 
14 4R S/S S/S 9R/10R 4R/4R A1/A2 G/G POSITIVE 0.30-LS 
15 3R L/L LA / LA 10R/10R 4R/4R A1/A2 A/G POSITIVE 0.69 –HS 
16 4R S/L S/LA 10R/10R 4R/7R A1/A2 A/A POSITIVE 0.46-MS 
Table 5. Group 1 genotyping data for each Caucasian patient. Data taken from Blum et al. 
2010. 
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The finding that 75% of these individuals have moderate-to-high GARS, whereas only 25% 
had low GARS, indicates that pre-screening patients prior enrolling in a treatment program 
could be beneficial. Clinically, this will be important for understanding expectations of 
future success and the need for intensive treatment involving genomic solutions coupled 
with medical therapies, including bio-holistic therapies. It will also reduce quilt and denial 
of the entering patient.  
 
Subject 
MAOAuVNT
R 
5HTTLPR 5HTTLPR SLC6A3 DRD4 DRD2 COMT
Any risk 
allele 
SEVERITY* 
GARS 
1 4R S/L S/LA 10R/10R 4R/4R A2/A2 A/A POSITIVE 0.30–LS 
2 3R S/S S/S 10R/10R 2R/4R A1/A2 GAG POSITIVE 0.38–MS 
3 4R S/S S/S 10R/10R 3R/4R A1/A2 G/G POSITIVE 0.46-MS 
4 3R S/S S/S 10R/10R 4R/6R A2/A2 G/G POSITIVE 0.38-MS 
5 4R S/S S/S 10R/10R 4R/4R A1/A2 A/G POSITIVE 0.30–LS 
6 3R L/L S/ LG 10R/10R 4R/4R A1/A2 ND POSITIVE 0.45 –MS 
7 4R L/L LA/LG 10R/10R 4R/4R A1/A2 A/G POSITIVE 0.54 –HS 
8 4R S/S S/S 10R/10R 4R/5R A2/A2 A/G POSITIVE 0.23-LS 
9 3R S/L S/LA 10R/10R 2R/4R A2/A2 A/G POSITIVE 0.46-MS 
Table 6. Group 2 genotyping data for each Chinese patient. Data taken from Blum et al 2010.  
The GARS study supports the understanding that identifying hypodopaminergic genotypes 
may be the best predictor of adult and adolescent drug abuse or other SUD behavior. These 
results are also consistent with a number of functional MRI studies that show that the 
hypodopaminergic DRD2 A1 genotype leads to blunted responses that can could lead to 
aberrant drug and/or food seeking behavior (Stice et al., 2008), while the 
hyperdopaminergic  A2 genotype serves as a protective factor against the development of 
drug disorders (Volkow et al 2006). 
A further strength of this study is that only male subjects were used. Males with 
hypodopaminegic functioning are more likely to abuse drugs that stimulate the 
mesocorticolimbic system than those with normal dopaminergic functioning. In contrast, 
females living in a negative environment are at increased risk (possibly not due to their 
genotypes) for using more drugs and even more types of drug that increase their risk for 
SUD.  
Another strength of this study is that it is in agreement with the work of Conner et al. [2010] 
confirming the importance of the cumulative effect of multiple genotypes coding for 
hypodopaminergic functioning, regardless of their genomic location, as a predictive method  
of drug use in males. Moreover, it extends the current literature, by suggesting for the first 
time a simple method using genetic testing to classify risk behavior in male patients seeking 
in-patient residential treatment (see table 7). 
6.3 A representative RDS gene panel   
Table 7, describes a RDS-associated gene/polymorphism panel that can be used in 
accordance with the potential development of the GARS test. 
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Gene Significance Comment 
ALDH2 P= 5 X 10-37 
With alcoholism and alcohol-
induced medical diseases 
ADH1B P= 2 X 10-21 
With alcoholism and alcohol-
induced medical diseases 
ADH1C P = 4 X 10-33 
With alcoholism and alcohol-
induced medical diseases 
DRD2 P =1 X 10-8 With alcohol and drug abuse 
DRD4 P= 1 X 10-2 With alcohol and drug abuse 
SLC6A4 P= 2 X 10-3 
With alcohol , heroin, cocaine, 
methamphetamine dependence 
HTRIB P= 5 X 10-1 With alcohol and drug abuse 
HTRI2A P= 5 X 10-1 With alcohol and drug abuse 
TPH P = 2 X 10-3 With alcohol and drug abuse 
MAOA P = 9 X 10-5 With alcohol and drug abuse 
OPRD1 P= 5 X 10-1 With alcohol and drug abuse 
GABRG2 P= 5 X 10-4 With alcohol and drug abuse 
GABRA2 P= 7 X 10-4 With alcohol and drug abuse 
GABRA6 P= 6 X 10-4 With alcohol and drug abuse 
COMT* P= 5 X 10-1 
With alcohol and drug abuse in 
Asians
DAT1 P= 5 X 10-1 
With alcohol and drug abuse in 
Asians
CNR1 P= 5 X 10-1 With alcohol and drug abuse 
CYP2E1* P =7 X10-2 With alcohol LIVER DISEASE 
Table 7. An RDS gene panel. Chen et al. Journal of Psychoactive drugs. June 2011.  
7. Conclusion 
The need to genetically test individuals, especially at entry into a residential or even non-
residential chemical dependency program, has long been recognized. In the GARS  study, a 
high percentage (75%) of subjects were found to carry a moderate to high GARS, and 100% 
of individuals tested possessed at least  one of the RDS risk alleles tested. It is of some 
interest that in the Group 2 population only rare DRD4 alleles such as 2R, 5R, and 6R were 
found. This study supports our understanding that hypodopaminergic state is due to gene 
polymorphisms, as well as environmental elements including both stress and neurotoxicity 
from aberrant abuse of psychoactive drugs (e.g., alcohol, heroin, cocaine etc). This study 
demonstrates that useful genetic variables include serotonergic genes (e.g., serotonergic 
receptors [5HT2a], serotonin transporter 5HTlPR, etc.), endorphinergic genes (e.g., mu 
OPRM1 gene, proenkephalin (PENK) [PENK polymorphic 3' UTR dinucleotide (CA) 
repeats]), and dopaminergic genes (e.g., ANKKI Taq A; DRD2 C957T, DRD4 7R, COMT 
Val/met substation, MAO-A uVNTR, and SLC3 9 or 10R). Future studies could add other 
genes (e.g., GABARB3) and D3 dopamine receptor. 
Any of these genetic and/or environmental impairments could result in reduced release of 
dopamine and or reduced number of dopaminergic receptors. The use of GARS will have 
prevention and treatment benefits in those patients afflicted with genetic antecedents to 
RDS-seeking behaviors.  
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